Lineage Cell Therapeutics Q1 Earnings Call Highlights

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Lineage Announces Formation of Scientific Advisory Board

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

Defender Capital LLC. Buys Shares of 6,829,099 Lineage Cell Therapeutics, Inc. $LCTX

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Lineage Cell Therapeutics Q4 Earnings Call Highlights

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript

Lineage Cell (LCTX) Reports Break-Even Earnings for Q4

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

Lineage Cell Therapeutics Issues Letter to Stockholders

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading 4.7% Higher – Should You Buy?

Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript

Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call Transcript

Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates

Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Squarepoint Ops LLC Takes $46,000 Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call Transcript

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Insiders Are Scooping Up These 5 Stocks Now

Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript